{
  "name": "ICH Q5A(R2) section and annex map",
  "description": "Section-by-section map of the ICH Q5A(R2) Step 4 guideline (1 November 2023) compiled from the full guideline text, listing each section or annex, its topic and the key content it holds.",
  "page": "https://casrai.org/guides/ich-q5a",
  "publisher": "CASRAI",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "dateModified": "2026-11-21T11:05:00Z",
  "temporalCoverage": "2023",
  "spatialCoverage": null,
  "columns": [
    {
      "name": "Section",
      "unit": "",
      "description": ""
    },
    {
      "name": "Topic",
      "unit": "",
      "description": ""
    },
    {
      "name": "Key content",
      "unit": "",
      "description": ""
    }
  ],
  "rows": [
    {
      "Section": "1",
      "Topic": "Introduction and scope",
      "Key content": "Biotherapeutics from human or animal cell lines; viral vectors in scope via Annex 6; prions, inactivated and live attenuated self-replicating vaccines excluded"
    },
    {
      "Section": "2",
      "Topic": "Potential sources of virus contamination",
      "Key content": "Sources of virus contamination"
    },
    {
      "Section": "3",
      "Topic": "Cell line qualification",
      "Key content": "3.1 cell banks (MCB, WCB, LIVCA); 3.2 assays including retrovirus, in vitro, in vivo, specific virus and molecular methods (NAT, NGS); 3.3 acceptability"
    },
    {
      "Section": "4",
      "Topic": "Testing of unprocessed bulk",
      "Key content": "Routine adventitious virus testing on each bulk; indicator cultures 28 days with sub-passage at 2 weeks, 14 days if justified"
    },
    {
      "Section": "5",
      "Topic": "Rationale and action plan",
      "Key content": "Rationale and action plan; Table 4 sets out Cases A to F"
    },
    {
      "Section": "6",
      "Topic": "Evaluation of viral clearance",
      "Key content": "6.1 virus choice; 6.2 design; 6.3 interpretation (about 4 log10 per effective step); 6.4 limitations; 6.5 statistics; 6.6 prior knowledge; 6.7 re-evaluation"
    },
    {
      "Section": "7",
      "Topic": "Continuous manufacturing",
      "Key content": "Sampling strategy justified; final release documents absence of viral contamination for the harvest period"
    },
    {
      "Section": "8",
      "Topic": "Summary",
      "Key content": "Summary of the guideline"
    },
    {
      "Section": "9",
      "Topic": "Glossary",
      "Key content": "Glossary"
    },
    {
      "Section": "Annex 1",
      "Topic": "Choice of viruses for clearance studies",
      "Key content": "Example model viruses; use not mandatory"
    },
    {
      "Section": "Annex 2",
      "Topic": "Statistical considerations",
      "Key content": "Statistical considerations"
    },
    {
      "Section": "Annex 3",
      "Topic": "Calculation of reduction factors",
      "Key content": "Ri = log10 of (volume x titre before) / (volume x titre after); individual factor used should be greater than 1"
    },
    {
      "Section": "Annex 4",
      "Topic": "Calculation of particles per dose",
      "Key content": "Calculation of particles per dose"
    },
    {
      "Section": "Annex 5",
      "Topic": "Prior knowledge examples",
      "Key content": "Solvent/detergent or detergent inactivation, low pH, virus filtration"
    },
    {
      "Section": "Annex 6",
      "Topic": "Viral vectors",
      "Key content": "AAV and virus-like particles within defined limits"
    }
  ],
  "sources": [
    {
      "title": "ICH Q5A(R2) Step 4 guideline",
      "url": "https://database.ich.org/sites/default/files/ICH_Q5A%28R2%29_Guideline_2023_1101.pdf",
      "accessed": "2026-11-19"
    }
  ]
}